Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Inspire Investing LLC

Inspire Investing LLC reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,044 shares of the company’s stock after selling 362 shares during the quarter. Inspire Investing LLC’s holdings in Omnicell were worth $403,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of OMCL. Victory Capital Management Inc. increased its stake in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the period. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell during the 3rd quarter worth approximately $32,721,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after buying an additional 259,463 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after buying an additional 243,353 shares during the period. Finally, Pier Capital LLC purchased a new stake in shares of Omnicell in the third quarter valued at approximately $5,859,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays increased their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Wells Fargo & Company cut their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Finally, Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $50.00.

Omnicell Price Performance

Shares of Omnicell stock opened at $43.63 on Friday. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The business has a 50 day moving average price of $44.60 and a 200 day moving average price of $42.14. The company has a market capitalization of $2.02 billion, a P/E ratio of -111.87, a P/E/G ratio of 29.73 and a beta of 0.78.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.